Evenity finally wins EU approval; US-China biologics CDMO raises $60M
→ Amgen and partner UCB have managed to convince the EMA to finally approve their bone-building drug, Evenity, to treat osteoporosis. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
